Før behandling Når behandling med simvastatin påbegyndes, eller dosis af simvastatin øges, skal alle patienter informeres om risikoen for myopati og instrueres i straks at rapportere alle uforklarlige muskelsmerter, ømhed eller svaghed.
Before the treatment All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness.